Literature DB >> 25519012

Evaluation of genetic variants in miRNAs in patients with colorectal cancer.

Panagiotis Dikaiakos1, Maria Gazouli2, Spyros Rizos1, George Zografos3, George E Theodoropoulos3.   

Abstract

BACKGROUND: Aberrant expression and structural alteration of miRNAs are considered to participate in cancer development. It has been suggested that common single-nucleotide polymorphisms (SNPs) in miRNAs are associated with susceptibility to several human diseases including colorectal cancer (CRC).
METHODS: A case-control study at 157 CRC patients and 299 healthy controls of Greek origin was undertaken in order to investigate the association between the genotype and allelic frequencies of three common SNPs (rs2910164, rs11614913 and rs3746444) in pre-miRNAs, miR-146a, miR-196a2 and miR-499.
RESULTS: The risk for CRC was significantly higher at the carriers of miR-146a rs2910164 CC genotype and C allele (p=0.02 and p< 0.001, respectively). None of the other performed analysis showed any statistically significant results.
CONCLUSIONS: Our findings suggest that the rs2910164 polymorphism in pre-miRNA, miR-146a may be associated with the risk of CRC.

Entities:  

Keywords:  Colorectal cancer; SNPs; miRNA; single nucleotide polymorphisms

Mesh:

Substances:

Year:  2015        PMID: 25519012     DOI: 10.3233/CBM-140449

Source DB:  PubMed          Journal:  Cancer Biomark        ISSN: 1574-0153            Impact factor:   4.388


  12 in total

1.  Association of four common SNPs in microRNA polymorphisms with the risk of hepatocellular carcinoma.

Authors:  Xinhong Li; Kai Li; Zhongjun Wu
Journal:  Int J Clin Exp Pathol       Date:  2015-08-01

2.  Association of the mir-499 polymorphisms with oral cavity and oropharyngeal squamous cell carcinoma in an Iranian population.

Authors:  Atefeh Akhani; Arash Motaghi; Maryam Ostad Sharif; Simin Hemati
Journal:  Dent Res J (Isfahan)       Date:  2020-05-23

Review 3.  Quantitative Assessment of the Association between Genetic Variants in MicroRNAs and Colorectal Cancer Risk.

Authors:  Xiao-Xu Liu; Meng Wang; Dan Xu; Jian-Hai Yang; Hua-Feng Kang; Xi-Jing Wang; Shuai Lin; Peng-Tao Yang; Xing-Han Liu; Zhi-Jun Dai
Journal:  Biomed Res Int       Date:  2015-05-20       Impact factor: 3.411

4.  Association of miR-196a2 rs11614913 and miR-499 rs3746444 polymorphisms with cancer risk: a meta-analysis.

Authors:  Wanjun Yan; Xiaoyan Gao; Shuqun Zhang
Journal:  Oncotarget       Date:  2017-11-20

Review 5.  rs11614913 polymorphism in miRNA-196a2 and cancer risk: an updated meta-analysis.

Authors:  Yuhan Liu; Anbang He; Baoer Liu; Yucheng Zhong; Xinhui Liao; Jiangeng Yang; Jieqing Chen; Jianting Wu; Hongbing Mei
Journal:  Onco Targets Ther       Date:  2018-03-01       Impact factor: 4.147

6.  A Meta-Analysis of miR-499 rs3746444 Polymorphism for Cancer Risk of Different Systems: Evidence From 65 Case-Control Studies.

Authors:  Xianglin Yang; Xuelian Li; Baosen Zhou
Journal:  Front Physiol       Date:  2018-06-12       Impact factor: 4.566

7.  miR-146a C/G polymorphism increased the risk of head and neck cancer, but overall cancer risk: an analysis of 89 studies.

Authors:  Dezhong Sun; Xiaoyan Zhang; Xiaolei Zhang
Journal:  Biosci Rep       Date:  2018-01-10       Impact factor: 3.840

8.  MiRNA Polymorphisms and Hepatocellular Carcinoma Susceptibility: A Systematic Review and Network Meta-Analysis.

Authors:  Qimeng Zhang; Xueying Xu; Mingcheng Wu; Tiantian Qin; Shaoning Wu; Hongbo Liu
Journal:  Front Oncol       Date:  2021-01-19       Impact factor: 6.244

9.  SNP Regulation of microRNA Expression and Subsequent Colon Cancer Risk.

Authors:  Lila E Mullany; Roger K Wolff; Jennifer S Herrick; Matthew F Buas; Martha L Slattery
Journal:  PLoS One       Date:  2015-12-02       Impact factor: 3.240

10.  MiR-196a2 and lung cancer in Chinese non-smoking females: a genetic association study and expression analysis.

Authors:  Zhihua Yin; Zhigang Cui; Yangwu Ren; Lingzi Xia; Hang Li; Baosen Zhou
Journal:  Oncotarget       Date:  2017-08-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.